193 related articles for article (PubMed ID: 33111087)
1. Repurposing the Native Type I-F CRISPR-Cas System in
Xu Z; Li Y; Yan A
STAR Protoc; 2020 Jun; 1(1):100039. PubMed ID: 33111087
[TBL] [Abstract][Full Text] [Related]
2. Native CRISPR-Cas-Mediated Genome Editing Enables Dissecting and Sensitizing Clinical Multidrug-Resistant P. aeruginosa.
Xu Z; Li M; Li Y; Cao H; Miao L; Xu Z; Higuchi Y; Yamasaki S; Nishino K; Woo PCY; Xiang H; Yan A
Cell Rep; 2019 Nov; 29(6):1707-1717.e3. PubMed ID: 31693906
[TBL] [Abstract][Full Text] [Related]
3. Repurposing type I-F CRISPR-Cas system as a transcriptional activation tool in human cells.
Chen Y; Liu J; Zhi S; Zheng Q; Ma W; Huang J; Liu Y; Liu D; Liang P; Songyang Z
Nat Commun; 2020 Jun; 11(1):3136. PubMed ID: 32561716
[TBL] [Abstract][Full Text] [Related]
4. CRISPR/Cas9-based Genome Editing of Pseudomonas aeruginosa.
Chen W; Ji Q
Methods Mol Biol; 2024; 2721():3-12. PubMed ID: 37819511
[TBL] [Abstract][Full Text] [Related]
5. Exploiting endogenous CRISPR-Cas system for multiplex genome editing in Clostridium tyrobutyricum and engineer the strain for high-level butanol production.
Zhang J; Zong W; Hong W; Zhang ZT; Wang Y
Metab Eng; 2018 May; 47():49-59. PubMed ID: 29530750
[TBL] [Abstract][Full Text] [Related]
6. Harnessing the native type I-B CRISPR-Cas for genome editing in a polyploid archaeon.
Cheng F; Gong L; Zhao D; Yang H; Zhou J; Li M; Xiang H
J Genet Genomics; 2017 Nov; 44(11):541-548. PubMed ID: 29169919
[TBL] [Abstract][Full Text] [Related]
7. Harnessing the type I CRISPR-Cas systems for genome editing in prokaryotes.
Xu Z; Li Y; Li M; Xiang H; Yan A
Environ Microbiol; 2021 Feb; 23(2):542-558. PubMed ID: 32510745
[TBL] [Abstract][Full Text] [Related]
8. Analysis of direct repeats and spacers of CRISPR/Cas systems type I-F in Brazilian clinical strains of Pseudomonas aeruginosa.
Luz ACO; da Silva JMA; Rezende AM; de Barros MPS; Leal-Balbino TC
Mol Genet Genomics; 2019 Oct; 294(5):1095-1105. PubMed ID: 31098740
[TBL] [Abstract][Full Text] [Related]
9. CRISPR-Cas9-Based Genome Editing and Cytidine Base Editing in
Wang Y; Wang Z; Ji Q
STAR Protoc; 2020 Jun; 1(1):100025. PubMed ID: 33111078
[TBL] [Abstract][Full Text] [Related]
10. Phylogenetic Distribution of CRISPR-Cas Systems in Antibiotic-Resistant Pseudomonas aeruginosa.
van Belkum A; Soriaga LB; LaFave MC; Akella S; Veyrieras JB; Barbu EM; Shortridge D; Blanc B; Hannum G; Zambardi G; Miller K; Enright MC; Mugnier N; Brami D; Schicklin S; Felderman M; Schwartz AS; Richardson TH; Peterson TC; Hubby B; Cady KC
mBio; 2015 Nov; 6(6):e01796-15. PubMed ID: 26604259
[TBL] [Abstract][Full Text] [Related]
11. Efficient genome editing for Pseudomonas aeruginosa using CRISPR-Cas12a.
Lin Z; Li H; He L; Jing Y; Pistolozzi M; Wang T; Ye Y
Gene; 2021 Jul; 790():145693. PubMed ID: 33961975
[TBL] [Abstract][Full Text] [Related]
12. A transferrable and integrative type I-F Cascade for heterologous genome editing and transcription modulation.
Xu Z; Li Y; Cao H; Si M; Zhang G; Woo PCY; Yan A
Nucleic Acids Res; 2021 Sep; 49(16):e94. PubMed ID: 34157103
[TBL] [Abstract][Full Text] [Related]
13. Genetic characteristics and phylogenetic analysis of Brazilian clinical strains of Pseudomonas aeruginosa harboring CRISPR/Cas systems.
de Oliveira Luz AC; da Silva Junior WJ; do Nascimento Junior JB; da Silva JMA; de Queiroz Balbino V; Leal-Balbino TC
Curr Genet; 2021 Aug; 67(4):663-672. PubMed ID: 33751147
[TBL] [Abstract][Full Text] [Related]
14. Efficient dual-negative selection for bacterial genome editing.
Cianfanelli FR; Cunrath O; Bumann D
BMC Microbiol; 2020 May; 20(1):129. PubMed ID: 32448155
[TBL] [Abstract][Full Text] [Related]
15. Optimized protocol to create deletion in adherent cell lines using CRISPR/Cas9 system.
Farooq U; Notani D
STAR Protoc; 2021 Dec; 2(4):100857. PubMed ID: 34746853
[TBL] [Abstract][Full Text] [Related]
16. A user-friendly and streamlined protocol for CRISPR/Cas9 genome editing in budding yeast.
Novarina D; Koutsoumpa A; Milias-Argeitis A
STAR Protoc; 2022 Jun; 3(2):101358. PubMed ID: 35712010
[TBL] [Abstract][Full Text] [Related]
17. Recent advances in CRISPR technologies for genome editing.
Song M; Koo T
Arch Pharm Res; 2021 Jun; 44(6):537-552. PubMed ID: 34164771
[TBL] [Abstract][Full Text] [Related]
18. Characterization and applications of Type I CRISPR-Cas systems.
Hidalgo-Cantabrana C; Barrangou R
Biochem Soc Trans; 2020 Feb; 48(1):15-23. PubMed ID: 31922192
[TBL] [Abstract][Full Text] [Related]
19. An efficient and versatile CRISPR-Cas9 system for genetic manipulation of multi-drug resistant
McConville TH; Giddins MJ; Uhlemann AC
STAR Protoc; 2021 Mar; 2(1):100373. PubMed ID: 33733242
[TBL] [Abstract][Full Text] [Related]
20. Protocol for precision editing of endogenous Chlamydomonas reinhardtii genes with CRISPR-Cas.
Nievergelt AP; Diener DR; Bogdanova A; Brown T; Pigino G
STAR Protoc; 2024 Mar; 5(1):102774. PubMed ID: 38096061
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
